KYSA-6

anti-CD19 CAR-T therapy · Kyverna Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KYSA-6, covering 2026-04-06 to 2026-04-06. Get the full timeline:

Most recent: Clinical Trial Update: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis [Phase 2, Phase 3]

See pricing